Affymetrix and Luminex Announce Distribution Agreement
News Oct 16, 2015
Affymetrix Inc. and Luminex Corporation have announced a distribution agreement under which eBioscience, a business unit of Affymetrix, will sell Luminex’s MAGPIX®, Luminex® 200™ and FLEXMAP 3D® multiplexed assay platforms in specified countries in the Americas, Asia and Europe.
Affymetrix will sell the Luminex instruments together with ProcartaPlex® multiplexed immunoassays and QuantiGene® Plex multiplexed quantitative gene expression assays, offering complete solutions to customers working in the fields of drug discovery and development, immuno-oncology and translational research.
The agreement will strengthen continued growth and adoption of Affymetrix’ bead-based assay portfolio, which serves markets growing at double-digit rates worldwide, while expanding the Luminex instrument installed base.
The distribution agreement covers the U.S., Canada, Mexico, Brazil and China as well as The Netherlands, Germany, France, U.K., Switzerland, Austria, Belgium, Ireland, Luxembourg and Poland.
“We are pleased to enter into this agreement with Luminex, the leading instrument provider supporting bead-based multiplexed assays,” said Dara Grantham Wright, senior vice president and general manager of the eBioscience business unit at Affymetrix. “This agreement deepens our relationship with Luminex, and will provide our customers an integrated solution to access a best-in-class platform with an ever-expanding, high-quality assay menu.”
“By enabling Affymetrix to offer both Luminex multiplexing instruments and Affymetrix assays, we can further drive accessibility to customers focused on disease-related research around the world,” said Todd Bennett, vice president, global sales and customer operations, Luminex Corporation.
Bennett continued, “We are very pleased to enter into this agreement, and to support Affymetrix in its efforts to bring flexible, high-quality solutions to laboratories working in the fields of drug discovery and development, immuno-oncology and translational research.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.